QT Imaging makes a medical imaging device called the QT Breast Scanner, which uses low-energy sound waves to produce 3D images of breast tissue — no radiation, no compression, and no contrast injections. The scanner is FDA-cleared as an adjunct to mammography, targeting women with dense breast tissue, high-risk younger women, and patients undergoing treatment monitoring. QT Imaging positions the scanner as a lower-cost, more comfortable alternative to breast MRI for patients who cannot or will not undergo MRI. The company sells the scanner to hospitals, radiology centers, and imaging facilities. In the U.S., NXC Imaging (a Canon Medical USA subsidiary) serves as the exclusive distributor; internationally, QT Imaging is building out regional distribution partners, starting with the Gulf region. Revenue today is primarily driven by hardware sales. QT Imaging is also building a tiered cloud SaaS platform called QTI Precision Pathway, which layers software updates, AI-driven diagnostics, and quantitative biomarker tools on top of installed scanners via an annual subscription — the goal being to shift the business toward a recurring-revenue model over time. A key constraint on growth is reimbursement: providers will only broadly adopt the scanner if insurers routinely pay for scans. The AMA approved a new Category III CPT code in early 2026, effective January 2027, which is a step toward standardized reimbursement, but routine insurance coverage is not yet established. Manufacturing is transitioning to Canon Medical Systems as contract manufacturer to support scaling.